Photodegradation of Dacarbazine Catalyzed by Vitamin B₂ and Flavin Adenine Dinucleotide Under Visible-Light Irradiation.

IF 3.5 3区医学 Q2 CHEMISTRY, MULTIDISCIPLINARY

Pharmaceutical Research Pub Date : 2024-12-18 DOI:10.1007/s11095-024-03802-2

Yuka Kimura, Mayuko Suga, Kayo Nakamura, Hidetsugu Tabata, Tetsuta Oshitari, Hideaki Natsugari, Hideyo Takahashi

{"title":"Photodegradation of Dacarbazine Catalyzed by Vitamin B2 and Flavin Adenine Dinucleotide Under Visible-Light Irradiation.","authors":"Yuka Kimura, Mayuko Suga, Kayo Nakamura, Hidetsugu Tabata, Tetsuta Oshitari, Hideaki Natsugari, Hideyo Takahashi","doi":"10.1007/s11095-024-03802-2","DOIUrl":null,"url":null,"abstract":"Purpose: Drug photodegradation is a matter of great concern because it can result in potency loss and adverse side effects. This study examines the light-induced degradation of dacarbazine catalyzed by vitamin B2 and flavin adenine dinucleotide (FAD) under light-emitting diode (LED) or fluorescent light irradiation.Methods: Dacarbazine was irradiated with LED (405 nm) or fluorescent light in the presence of various equivalents of vitamin B2 or FAD. The photodegradation of the drug in D2O was monitored by 1H nuclear magnetic resonance spectroscopy.Results: Dacarbazine dissolved in D2O decomposed in the presence of vitamin B2 or FAD under irradiation with LED or fluorescent light. The decomposition products were 2-azahypoxanthine 2, which has previously been observed after light irradiation in the absence of vitamin B2, and 1H-imidazole-5-carboxamide 6, a new product formed in the presence of vitamin B2. Irradiation with LED light was more effective than irradiation with fluorescent light in degrading dacarbazine.Conclusion: Vitamin B2 and FAD induced dacarbazine photodegradation. Thus, the interfusion of vitamin B2 or FAD under excessive light exposure should be avoided during the intravenous administration of dacarbazine.","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11095-024-03802-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Drug photodegradation is a matter of great concern because it can result in potency loss and adverse side effects. This study examines the light-induced degradation of dacarbazine catalyzed by vitamin B₂ and flavin adenine dinucleotide (FAD) under light-emitting diode (LED) or fluorescent light irradiation.

Methods: Dacarbazine was irradiated with LED (405 nm) or fluorescent light in the presence of various equivalents of vitamin B₂ or FAD. The photodegradation of the drug in D₂O was monitored by ¹H nuclear magnetic resonance spectroscopy.

Results: Dacarbazine dissolved in D₂O decomposed in the presence of vitamin B₂ or FAD under irradiation with LED or fluorescent light. The decomposition products were 2-azahypoxanthine 2, which has previously been observed after light irradiation in the absence of vitamin B₂, and 1H-imidazole-5-carboxamide 6, a new product formed in the presence of vitamin B₂. Irradiation with LED light was more effective than irradiation with fluorescent light in degrading dacarbazine.

Conclusion: Vitamin B₂ and FAD induced dacarbazine photodegradation. Thus, the interfusion of vitamin B₂ or FAD under excessive light exposure should be avoided during the intravenous administration of dacarbazine.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical Research 医学-化学综合

CiteScore

6.60

自引率

5.40%

发文量

276

审稿时长

3.4 months

期刊介绍： Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, is committed to publishing novel research that is mechanism-based, hypothesis-driven and addresses significant issues in drug discovery, development and regulation. Current areas of interest include, but are not limited to: -(pre)formulation engineering and processing- computational biopharmaceutics- drug delivery and targeting- molecular biopharmaceutics and drug disposition (including cellular and molecular pharmacology)- pharmacokinetics, pharmacodynamics and pharmacogenetics. Research may involve nonclinical and clinical studies, and utilize both in vitro and in vivo approaches. Studies on small drug molecules, pharmaceutical solid materials (including biomaterials, polymers and nanoparticles) biotechnology products (including genes, peptides, proteins and vaccines), and genetically engineered cells are welcome.